Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Hepatitis C: Update Bulletin [August 2014]

Product Code:
Release Date:
July 2014

Gain new KOL insights on the latest events happening in Hepatitis C: Janssen-Cilag/Medivir; Olysio; Gilead; sofosbuvir; ledipasvir; AbbVie; 3D combination; access to new HCV therapies

Highlights from this event update bulletin

  • Olysio (simeprevir) approved in Europe, but long-term outlook dim
  • Enthusiasm for Gilead’s FDC of sofosbuvir and ledipasvir remains strong despite flurry of activity in HCV pipeline
  • The potential advantages of AbbVie’s 3D regimen are starting to lose traction among KOLs
  • Highly effective yet expensive drugs for hepatitis C have payers scrambling to develop policy
  • Price and payer policies will exert greater influence on regimen choice in near future

When you purchase the full report, you get access to this Update Bulletin.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved